Zentalis Pharmaceuticals, Inc.
No SEC Form 4 filings for $ZNTL in the last 30 days.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zntlq22026pressrelease.htm EX-99.1 Document Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrol
ManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zntl-20260616 0001725160 FALSE 0001725160 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Dat
Over the past 7 days, alphai's AI scored 1 news story mentioning ZNTL (Zentalis Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ZNTL coverage spans financial news, earnings and corporate actions.
FDA alignment on dose and study population plus updated cash runway and DENALI enrollment status are near-term catalysts for biotech risk pricing.
ManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
The filing is a corporate governance update; it does not disclose new financial guidance, deals, or regulatory outcomes.
Equity inducement grant is a modest dilution/overhang item but typically not a fundamental catalyst; main trading relevance is near-term sentiment/flow around the grant details.
The announcement of inducement grants under Nasdaq Rule 5635(c)(4) indicates ongoing management incentives, which may signal confidence in future growth. The somewhat-bullish sentiment (score: 0.165) suggests a modest positive market perception.
alphai scores every news story that mentions ZNTL with an AI model for sentiment and relevance, and aggregates insider trades from Zentalis Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zntlq22026pressrelease.htm EX-99.1 Document Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrol
6 min readManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
2 min readZentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zntl-20260616 0001725160 FALSE 0001725160 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Dat
3 min readZentalis Pharmaceuticals (Nasdaq: ZNTL) said its Compensation Committee granted non-qualified stock options to two newly hired employees on June 1, 2026, totaling 191,000 shares under Nasdaq Listing Rule 5635(c)(4). Options have a $3.98 exercise price, a 10-year term, and 4-year vesting (25% at year one, then monthly over three years), subject to continued service.
2 min readSAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, ...
2 min readSAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the ...
2 min readSAN DIEGO, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...
2 min readSAN DIEGO, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...
2 min readSAN DIEGO, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...
2 min readSAN DIEGO, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc.
2 min read
